Abstract: This invention relates to an efficient and enantioselective synthesis of the spiro-compounds of formula (1) as common intermediate, featuring an asymmetric introduction of the all-carbon quaternary centre in high selectivity and a very efficient one-pot procedure for the C2 elongation to generate the spiro-structure. For the all-carbon quaternary centre, a Tsuji-Trost asymmetric allylic alkylation (AAA) process was designed to develop a sustainable procedure with very low catalyst loading, thereby also facilitating the Pd content control in the product, under practically solvent free conditions. Furthermore, multiple synthetic transformations in a one-pot procedure were implemented by using a one-pot procedure either in form of a three-transformation sequence comprising Hydroboration-Alkylation-Dieckmann Condensation to compound of formula (1) or in form of a five-transformation sequence comprising Hydroboration-Alkylation-Dieckmann Condensation-Hydrolysis-Decarboxylation to compound of formula (9).

Abstract: The present invention relates to a method for the synthesis of a halo olefin of formula (I) wherein Hal, R1, R2, R3, R4, X and Y are as defined herein, or a salt thereof.

Abstract: The present invention relates to a method for the synthesis of a halo olefin of formula (I) wherein Hal, R1, R2, R3, R4, X and Y are as defined herein, or a salt thereof.

Abstract: The present invention relates to a method for the synthesis of a halo olefin of formula (I) wherein Ha1, R1, R2, R3, R4, X and Y are as defined herein, or a salt thereof.

Abstract: The present invention relates to a method for the synthesis of a halo olefin of formula (I) wherein Hal, R1, R2, R3, R4, X and Y are as defined herein, or a salt thereof.

Abstract: The present invention relates to a method for the synthesis of a halo olefin of formula (I) wherein Hal, R1, R2, R3, R4, X and Y are as defined herein, or a salt thereof.

Abstract: The present invention relates to a method for the synthesis of a halo olefin of formula (I) wherein Hal, R1, R2, R3, R4, X and Y are as defined herein, or a salt thereof.

Abstract: This invention relates to methods for making oxetan-3-ylmethanamines having the formula (I) wherein R1? and R2? are as defined herein. The methods of the invention provide the compounds of formula (I) in high yields and under conditions amenable for large-scale commercial production.

Abstract: Disclosed is a process for making diastereomeric N-sulfinyl ?-amino amides by reaction of chiral sulfinimines with formamides and lithium diisopropylamide. The process of the invention provides the N-sulfinyl ?-amino amides in high yields and with high diastereoselectivity.

Abstract: This invention relates to methods for making oxetan-3-ylmethanamines having the formula (I) wherein R1? and R2? are as defined herein. The methods of the invention provide the compounds of formula (I) in high yields and under conditions amenable for large-scale commercial production.

Abstract: Disclosed is a process for making diastereomeric N-sulfinyl ?-amino amides by reaction of chiral sulfinimines with formamides and lithium diisopropylamide. The process of the invention provides the N-sulfinyl ?-amino amides in high yields and with high diastereoselectivity.

Abstract: Disclosed is a process for making diastereomeric compound of the formula (I): wherein m, n and R1 to R4 are as defined herein. The process of the invention provides the compound of formula (I) in high yield and substantially free of the corresponding diastereomers. The compounds of formula (I) prepared by the process of the invention are useful for making pharmaceutically active compounds such as 11-?-hydroxysteroid hydrogenase type 1 (11-?-HSD1) inhibitors.

Abstract: A system and method are described that model a passive multiplexer, which may be used for a junction of a plurality of signal filters (e.g., radio frequency, microwave, satellite, etc.). Illustratively, based on obtaining parameters for the individual signal filters, an initial resonant frequency offset vector estimation may be calculated and input into a convergence algorithm to determine a set of multiplexer parameters. In particular, the convergence algorithm is generally different from the initial resonant frequency offset vector estimation calculation, and the initial resonant frequency offset vector estimation assists in achieving better (e.g., faster, more frequent) convergence on a set of multiplexer parameters from the convergence algorithm.

Abstract: Compounds of Formula (I) wherein R1, R2, X, and Y are as defined herein, or a tautomer, optical isomer, prodrug, co-crystal, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.

Abstract: Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are intermediates thereof, and methods of making and methods of using same.

Abstract: Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are intermediates thereof, and methods of making and methods of using same.

Abstract: A process for stereoselective synthesis of a compound of Formula (I) wherein R1, R2, R3, R4, and R5 are as described herein.

Abstract: Disclosed are processes for preparing compounds of formula (I): the compounds are useful as intermediates for preparing indazole and azaindazole substituted compounds.

Abstract: Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are methods of making and methods of using same.

Abstract: Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are methods of making and methods of using same.